[EN] 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS<br/>[FR] INHIBITEURS DE GLUCOSYLCÉRAMIDE SYNTHASE DE TYPE 2-ACYLAMINOPROPOANOL
申请人:GENZYME CORP
公开号:WO2010039256A1
公开(公告)日:2010-04-08
A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
[EN] PHENYL ACETAMIDES AS SPLA2 INHIBITORS<br/>[FR] PHENYL ACETAMIDES UTILISES COMME INHIBITEURS DE SPLA2
申请人:ELI LILLY AND COMPANY
公开号:WO1998024756A1
公开(公告)日:1998-06-11
(EN) A class of novel phenyl acetamides is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.(FR) La présente invention concerne une classe de nouveaux phényl acétamides ainsi que l'utilisation de ces composés s'agissant d'inhiber la libération des acides gras à médiation sPLA2 de manière à traiter des troubles tels qu'un choc septique.